• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog
  • News & Events
  • Videos
  • Resources
main-logo-small

Compliance Architects

Consulting Technology Outsourcing

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Deputy Assistant US Attorney General Outlines New Approaches for Enforcement of FDA-Regulated Companies

Food and Drug Law Institute LogoOn Thursday, December 7, Deputy Assistant Attorney General Ethan P. Davis, US Department of Justice, Consumer Protection Branch, gave a speech at the Food and Drug Law Institute Enforcement Litigation and Compliance Conference in Washington, DC. In this speech, Deputy Assistant Attorney General Davis outlined what may be the first tangible, specific public policy guidance on enforcement that FDA regulated industry has received from the new administration.

In the speech, Deputy Assistant Attorney General Davis stated that the Consumer Protection Branch is responsible for DOJ’s efforts to “enforce statutes designed to protect the health, safety and economic security of American consumers” and that the FDA is one of the Consumer Protection Branch’s key partners.   Deputy Assistant Attorney General Davis even provided a personal reflection regarding the importance of safe food, drugs and devices to all Americans, by offering that his family, with a nine-year-old son, is concerned with giving their son “only the best and safest foods and medicines” but also reflected that, as “[he has] quickly found out, [he] can’t protect [his son] from everything.”

The cornerstone policy positions were outlined under a section heading in the transcript entitled “The Rule of Law.”    This is where the key elements of the Department’s policy are revealed, and reveal a number of key themes:

  1. DOJ is ensuring that industry “has the room to continue to innovate”, and
  2. That “the rule of law” is a critical part of DOJ’s approach to “accomplishing [that] mission.”

The Deputy Assistant Attorney General then expands on this principle of the Rule of Law phase and states, that the “rule of law” is based on the principle that the United States is governed by law “and not by the arbitrary decisions of government officials” and that the rule of law is about “consistency and predictability”.

Immediately following, and in what appears to this author to be a principle quite in conflict with the foregoing goals, the Deputy Assistant Attorney General then outlines DOJ’s efforts to “roll back unnecessary regulations” and to end the practice of DOJ creating “binding obligations” through the issuance of guidance documents.   In other words, DOJ believes that simple notice and comment rulemaking is sufficient (and apparently preferable) to Agencies (in this case DOJ) providing formal guidance to regulated parties.  How this increases “consistency and predictability” in the rule of law is not clear – to me anyway.

The next main topic covered by the Deputy Assistant Attorney General is the topic of enforcement discretion.  Citing language from Attorney General Robert Jackson from 75 years ago that “no prosecutor can even investigate all of the cases in which he receives complaints,” the Deputy Assistant Attorney General re-affirmed Attorney General Jackson’s philosophy, and affirmed it as DOJ’s current philosophy, i.e., that it will “select the cases … in which the offense is the most flagrant, the public harm the greatest, and the proof the most certain.”

Continuing on, and weaving in his prior statements concerning the policy of regulatory roll-backs, the Deputy Assistant Attorney General posited that because there are “thousands of criminal offenses and thousands more laws that can form the basis of civil liability” and by also looking at the “hundreds of thousands of federal regulations – many inaccessible or incomprehensible” then how do people in the private sector possibly know what conduct will trigger a government investigation?   The Deputy Assistant Attorney General goes further and states that:

the existence of so many laws located in so many places can undermine confidence in the rule of law as evenhanded, accessible, and just. And when you all cannot predict what conduct will end up triggering an investigation by the Justice Department, our enforcement efforts operate to chill innovation.

So where does this clear policy approach leave the Deputy Assistant Attorney General and the Department’s approach to investigations and pursuit of bad actors?  He continues with how these cases will be approached:

[W]hen a new investigation or a potential indictment crosses my desk, I ask myself, and my team, a few questions: Is this a case where people got hurt, or where there was a clear threat of harm? Is this a case where people got defrauded? Is this a case where the target of the investigation acted knowingly or recklessly? If the answer to those questions is “yes,” we will pursue the matter vigorously in the name of protecting the health, safety, and economic security of the American consumer.

The Deputy Assistant Attorney General closes this part of the speech with the following:

The point of this exercise is to weed out technical regulatory violations in order to focus our enforcement resources on practices that threaten consumer health or safety.

*  *  *

Using the Department of Justice’s resources to pursue one-off technical regulatory violations where no one was hurt or defrauded, and where there was no clear risk of consumer harm, does not promote consumer health, safety, or economic security. It only forces companies to over-emphasize technical compliance issues — often involving rules that take a lot of effort to interpret — instead of focusing their resources on developing new, lifesaving medicines and devices.

The third part of the speech outlined enforcement action priorities for DOJ and Consumer Protection Board and includes opioids, dietary supplements and compounding pharmacies.  Characterizing these industry participants as largely “law abiding” companies, DOJ / CPB will focus – especially in the case of dietary supplements – on the “bad apples” of the industry – whoever they are.

During the fourth and final part of the speech,, the Deputy Assistant Attorney General addressed what is known as The Park Doctrine.[1]   This doctrine has been a backbone of Food and Drug Law and enforcement approaches since the earlier United States v. Dotterweich, 320 U.S. 277 (1943).   Now however, the Department of Justice will no longer consider violations of the law alone a sufficient basis for prosecutions.  As the Deputy Assistant Attorney General states:

[I]n evaluating Park prosecutions, we consider whether the unlawful conduct implicates public safety or has resulted in physical harm to individuals. We also look for actual knowledge or willful blindness as to the unlawful conduct on the part of each individual we are considering charging. And we generally avoid getting involved in good faith scientific disputes, because we do not want to stifle scientific exploration and debate, nor do we wish to put those researching creative or innovative means of medical care in fear of criminal liability.

These policy statements are a significant change in direction and approach from prior Administrations, Democratic or Republican, towards the protection of consumers by the Department of Justice.   Overall, bad actors will have more license to act because of greater deference towards what may constitute “egregious” conduct or “physical harm” to individuals.  Whether there will be practical implications to these changes is of course, unknown, and will have to be viewed through the lens of history – not through the distortion of a crystal ball.

[1]  UNITED STATES v. PARK, 421 U.S. 658 (1975), standing for the proposition that “responsible individuals” may be held personally liable for acts in violation of the Federal Food Drug and Cosmetic Act regardless of their individual knowledge of or participation in the violative conduct.

Download the transcript of the Deputy Assistant Attorney General’s speech here

Filed Under: FDA Enforcement Tagged With: Enforcement, FDA Enforcement, FDA guidance

Primary Sidebar

Sign Up To Our Newsletter

You May Also Like

Proud to be a Silver Sponsor of RIC’s Inaugural Annual Meeting! Join us March 22-23, 2023 at Convene in Arlington, VA!

Compliance Architects is proud to be Silver Sponsor of this year's RIC's inaugural annual meeting! The REMS Industry Consortium fosters collaboration and innovation to advance

Join the Team at Compliance Architects as our Content Marketing Manager!

This excellent opportunity will require the successful candidate to lead the technical content marketing and marketing automation activities as well as enable, manage, and drive
life sciences staffing

Talk to us about current talent trends, and what the industry will need in the next 5 to 10 years?

Transcript taken from 2022 PMWS by Executive Platforms The talent crisis as it has been called is certainly not something that has gone away or

Footer

Compliance Architects®

  • Contact Us
  • (888) 734-9778
  • info@compliancearchitects.com

Quick Links

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Our Services

  • Inspection Readiness & Enforcement
  • FDA Quality Consulting – Systems and Training
  • Quality Assurance and Engineering
  • Corporate Compliance and Litigation Services
  • FDA Regulatory Consultants – Due Diligence
  • Quality, Compliance, Regulatory & Operations’ Staffing Services

Proprietary Solutions

  • Writing for Compliance®
  • Quality Pulse®
  • CRPN Quality Roadmap®

© 2009-2023 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.

  • Debarment Certification Statement
  • Privacy Policy
  • Terms of Use

Contact Us Today

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT